Constipation, a prevalent gastrointestinal disorder, often poses diagnostic and therapeutic challenges in clinical practice. A comprehensive approach is crucial for effective management.
Before initiating treatment for constipation, a thorough clinical evaluation is essential. This includes a detailed patient history, physical examination, and when necessary, specialized tests such as colonic transit studies, anorectal manometry, or defecography. The goal is to differentiate functional constipation from secondary causes and other defecatory disorders.
Management strategies should be individualized, starting with lifestyle modifications, including dietary changes and physical activity. Pharmacological treatment may be considered if these measures are ineffective. Bulk-forming, osmotic, and stimulant laxatives are commonly used. Newer agents such as lubiprostone, linaclotide, and plecanatide can be considered for patients with chronic idiopathic constipation.
In patients with dyssynergic defecation, biofeedback therapy is considered the first-line treatment. It is a non-invasive, safe, and effective therapy that improves symptoms by retraining the pelvic floor muscles.
Surgery should be considered as a last resort, only for patients with severe, refractory constipation, and after careful evaluation. Procedures such as subtotal colectomy and ileorectal anastomosis can provide relief in carefully selected patients.
Understanding the complexities of constipation diagnosis and treatment is key to successful patient management. A comprehensive, patient-centered approach that encompasses lifestyle modifications, pharmacological treatment, and when necessary, biofeedback therapy or surgery, can help untangle the knot of constipation in clinical practice.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation